Relay Therapeutics Intrinsic Stock Value – Relay Therapeutics, Poised to Beat Earnings Estimates: Is It Time to Buy?
October 31, 2023
☀️Trending News
Relay Therapeutics ($NASDAQ:RLAY), Inc. is poised to beat earnings estimates and investors are asking if it is the right time to buy. This biotechnology company has been making strides in the industry with its revolutionary approach to discovering new medicines and therapies for serious diseases. The company is focused on using protein motion as a source of drug discovery that seeks to change the way diseases are treated. With its unique approach and promising prospects, Relay Therapeutics, Inc. is one of the most exciting stocks in the biotech market. The company currently has three drug candidates in clinical trials and its stock has been performing well over the last several months. Analysts expect Relay Therapeutics, Inc. to outperform earnings estimates and the stock is expected to rise even further in coming months. Investors looking for a growth opportunity should consider getting into this stock now before it takes off. The company has a solid management team with decades of experience in developing innovative therapies and it is well-positioned to capitalize on the growing demand for new treatments in the healthcare industry. With its strong fundamentals and potential for success, Relay Therapeutics, Inc. is an attractive stock for investors who are looking for long-term growth.
However, given its potential for success and the fact that it has already performed well in the market, now may be just the right time to invest in Relay Therapeutics, Inc.
Earnings
Relay Therapeutics, Inc. recently released its FY2023 Q2 earnings report as of June 30 2021. The report showed that the company had earned a total of 0.84M USD in revenue, but had lost 193.4M USD in net income. Compared to the previous year, this represented a 133.3% increase in total revenue; however, losses still remain high. Over the past three years, RELAY THERAPEUTICS’s total revenue has increased from 0.84M USD to 0.12M USD.
Given these results, it may be prudent to ask: Is it a good time to buy RELAY THERAPEUTICS’s stock? Analysts are optimistic about the company’s potential and believe that it could be a good investment in the long-term. Investors should take the time to do their own research before deciding whether or not to purchase RELAY THERAPEUTICS stock.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Relay Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0.94 | -344.42 | -37670.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Relay Therapeutics. More…
| Operations | Investing | Financing |
| -258.95 | 6.84 | 290.41 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Relay Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 962.02 | 151.9 | 6.66 |
Key Ratios Snapshot
Some of the financial key ratios for Relay Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -39958.3% |
| FCF Margin | ROE | ROA |
| -28321.0% | -27.8% | -24.5% |
Price History
On the same day, its stock opened at $6.0 and closed at $6.3, showing a 5.3% increase from the previous closing price of $6.0. This suggests that investors are expecting positive earnings results from the company. Given the rise in stock prices on Thursday, the question remains: is this the time to buy Relay Therapeutics stock? The answer could lie in the upcoming earnings report.
If the company is able to meet or exceed the current market expectations, then it could be a good opportunity for investors to purchase Relay Therapeutics stock. On the other hand, if the earnings report fails to meet expectations, then investors could see a decline in stock prices. Live Quote…
Analysis – Relay Therapeutics Intrinsic Stock Value
At GoodWhale, we took a close look at the wellbeing of RELAY THERAPEUTICS. With our proprietary Valuation Line, we calculated their intrinsic value to be around $7.5 a share. Right now, RELAY THERAPEUTICS’ stock is being traded at $6.3, undervalued by 15.8%. This makes it a fair price to invest in the company’s shares. More…
Peers
The company uses artificial intelligence to design and develop small molecule therapeutics for cancer patients. Relay Therapeutics Inc’s competitors include Kronos Bio Inc, Aadi Bioscience Inc, and Ikena Oncology Inc.
– Kronos Bio Inc ($NASDAQ:KRON)
Kronos Bio Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation cancer therapies. The company’s lead product candidate is entospletinib, a selective inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) family of proteins. Kronos Bio Inc has a market cap of 146.46M as of 2022, a Return on Equity of -33.99%. The company’s focus on the discovery and development of next-generation cancer therapies makes it an attractive option for investors interested in the healthcare sector.
– Aadi Bioscience Inc ($NASDAQ:AADI)
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of cancer. The company’s lead candidate is AB101, a first-in-class small molecule inhibitor of the MDM2-p53 interaction. AB101 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors. In addition to AB101, the company has a pipeline of other small molecule MDM2 inhibitors at various stages of development.
Aadi Bioscience Inc has a market cap of 305.67M as of 2022. The company’s return on equity for the same period is -72.24%. The company’s market cap and ROE are both indicative of a high-risk, high-reward investment. The company’s focus on developing novel cancer therapeutics gives it the potential to generate significant returns for investors, but the risks associated with clinical-stage drug development are also high.
– Ikena Oncology Inc ($NASDAQ:IKNA)
Ikena Oncology Inc is a clinical stage biopharmaceutical company, developing cancer therapies. The company’s focus is on developing small molecule inhibitors of the MYC protein. MYC is a protein that is overexpressed in many types of cancer and is thought to be a major driver of tumor growth. Ikena’s lead drug candidate, IK-172, is currently in clinical trials for the treatment of several types of solid tumors.
Ikena has a market cap of 92.44M as of 2022 and a Return on Equity of -16.89%. The company’s focus is on developing small molecule inhibitors of the MYC protein. MYC is a protein that is overexpressed in many types of cancer and is thought to be a major driver of tumor growth. Ikena’s lead drug candidate, IK-172, is currently in clinical trials for the treatment of several types of solid tumors.
Summary
Investing in Relay Therapeutics, Inc. can be a lucrative move, as the company is expected to beat earnings estimates. On the same day, the stock price of Relay Therapeutics moved up, which indicates investor confidence in the company. Investors should consider factors such as the company’s past performance, financials, and competitive landscape when researching Relay Therapeutics prior to investing.
Additionally, investors should pay close attention to news releases and company updates as they can affect the stock price. Overall, Relay Therapeutics looks like a promising investment option that could yield positive returns in the long run.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
